There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report.

An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer ...

Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...

Stay updated on the latest advancements in bladder cancer treatment and the financial decisions of a leading company in the ...

A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

Discover the trials that have shown why Predictive biomarkers are expected to play a pivotal role in further enhancing ...

Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s ...

Protara Therapeutics’ investigational cell therapy elicited a complete response (CR) rate of 72% among 18 patients with ...

Dogs trained to detect bladder cancer showed 90% sensitivity and 95% specificity, offering a non-invasive diagnostic method.

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder ...